Background: Anterior uveitis (AU) is the most common pattern of uveitis, that migh lead to important ocular complications including blindness. Immunomodulatory drugs have been used in order to prevent recurrences of uveitis. Nevertheless, it is not clear which drug could be preferred in each patient. Objectives: To generate recommendations on the use of immunomodulators in adult patients with non-infectious, non-neoplastic anterior uveitis (AU) based on best evidence and experience. Methods: Delphi methodology was followed. A multidisciplinary panel of 5 experts (2 ophtalmologists, one immunologist, one rheumatologist, one internist) was established, who, in the first nominal group meeting, defined the scope, users, and chapters of the document. A systematic literature review was performed to assess the efficacy and safety of immunomodulators in patients with non-infectious, non-neoplastic AU. All of the exposed above was discussed in a second nominal group meeting and 33 recommendations were generated. Recommendations agreement grade was tested also in 25 additional experts. Recommendations were voted from 1 (total disagreement) to 10 (total agreement). We defined agreement if at least 70% voted ≥7. The level of evidence and grade or recommendation was assessed using the Oxford Centre for Evidence-based Medicine Levels of Evidence. Results: The 33 recommendations were accepted. They include specific recommendations on patients with non-infectious, non-neoplastic UA, as well as different treatment lines. Methotrexate (MTX) or Sulfasalazine were recommended as a first line drugs in refractory cases to topic treatments in patients with AU and spondyloarthritis, inflammatory bowel disease, psoriasis, idiopathic HLA-B27 positive or negative AU. Etanercept was recommended for patients with TRAPS syndrome, and for those with other autoinflammatory syndromes canakinumab o anakinra. In case of bilateral sarcoidosis, relapsing polychondritis or TINU syndrome, MTX was recommended along with systemic steroids. For patients with a flare of AU and Behçet disease, systemic steroids along with azathioprine or a calcineurin inhibitor were recommended. The indication of an immunomodulatory drug in patitnes with multiple sclerosis was considered to be decided with a neurologist. For patients refractory to all exposed above and or intolerant, depending on AU type, a change to another classical immunomodulatory drug or to an anti-TNF was recommended (adalimumab, infliximab, certolizumab or). Except for patients with TINU, etanercept was not recommended because current evidence does not support the use of it to prevent AU flares.
FRI0603 CLINICAL IMPLICATIONS OF ULTRASONOGRAPHY IN MONITORING DISEASE ACTIVITY OF RELAPSING POLYCHONDRITIS: THE ASSESSMENT OF AURICULAR CHONDRITIS IN 3 CASES
H. Nishikawa, Y. Taniguchi, Y. Terada. Kochi Medical School, Nankoku, Japan Background: Relapsing polychondritis (RP) is a rare systemic inflammatory disorder and might often be refractory. Therefore, the discover of imaging modality would be required on diagnosis and treatment of RP. Objectives: To assess the clinical implications of ultrasonography (US) in monitoring disease activity of relapsing polychondritis (RP). Background: Immune checkpoint inhibitors (CPIs) have significantly improved outcomes for patients with various cancers. However, CPIs are associated with immune-related adverse events (irAEs). Two to three percent of patients receiving a CPI develop arthritis. In general, severe irAEs are treated with a high-dose steroid and a tumor necrosis factor inhibitor (TNFi), usually infliximab; however, TNFi treatment is sometimes contraindicated and, furthermore, entails a theoretical concern of impairing antitumor immunity. Therefore, evidence showing the clinical benefits of non-TNFi biologics in the treatment of irAEs is of immediate interest. Objectives: We described the effects of anti-IL-6R antibody for the treatment of arthritis-irAE. Methods: Three patients receiving CPI developed arthritis and were treated with anti-IL-6R antibody. Patients were followed up to 15 months. Results: All patients had metastatic melanoma (Table 1) . No patient had a history of autoimmune disease at the time of initiation of CPI treatment. One patient developed arthritis 8 weeks after the completion of anti-CTLA-4 antibody treatment. Two patients were receiving anti-PD-1 antibody when they developed arthritis. Patient 2 continued to receive anti-PD-1 antibody despite of arthritis-irAE while patient 3 discontinued anti-PD-1 antibody due to arthritis-irAE. The pattern of arthritis was symmetric polyarthritis involving small and large joints. Patient 1 had a positive rheumatoid factor (unknown baseline) and patient 3 had a positive ANA (known positive prior to CPI treatment). All patients were treated with anti-IL-6R antibody, which was well tolerated. All patients experienced a 40-100% reduction in global assessment, swollen joint count, and tender joint count, and these effects were maintained for up to 15 months of treatment ( Figure  1) . As of December 2016, all patients were alive; one patient was in complete remission and two patients had experienced progression of their melanoma. Conclusions: These three cases suggest that anti-IL-6R antibody is an effective alternative to TNFi for the treatment of arthritis-irAE. Background: Raynaud's phenomenon (RP) is a prominent manifestation of handarm vibration syndrome (HAVS). Previous studies have evaluated the diagnostic validity and characteristics of hand perfusion scintigraphy. However, no study to date has classified or differentiated the findings of this technique based on the aetiology of RP. Objectives: This study aimed to evaluate the hand perfusion scintigraphic features of hand-arm vibration syndrome (HAVS) and to compare these with the features of primary and secondary Raynaud's phenomenon (RP) associated with connective tissue disease (CTD). Methods: Hand perfusion scintigraphy was performed in 57 patients with primary RP, 71 patients with HAVS-related RP, and 36 patients with CTD-related RP. We calculated 6 ratios by using the time-activity curve and static blood pool images, the chilled to ambient hand and wrist ratios of the first peak height, initial slope, and blood pool uptake. We analysed 3 morphologic characteristics: slow progress pattern, paradoxically increased uptake pattern in the time-activity curve, and the inhomogeneous radioactivity uptake in the blood pool image. Results: All of the 71 patients with HAVS-related RP were mine workers. The onset of RP after exposure to vibration was at 21.8±7.3 years, with 26.3±7.0 years of vibration exposure time. The chilled to ambient hand ratios of the first peak height and the initial slope were significantly lower in patients with HAVS-related occupational RP than in patients with primary RP. The presence of a paradoxically increased uptake pattern was significantly lower in HAVS than in primary RP. Conclusions: There were significant differences in hand perfusion scintigraphic features between primary RP and HAVS. These results suggest that the underlying pathophysiology of the two diseases differs; thus, different criteria might be applied for their evaluation References: [1] Palmer KT, Bovenzi M. Rheumatic effects of vibration at work. Best Pract Res Clin Rheumatol 2015;29:424-39.
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